Adenosine-Based Approaches

The adenosine A2A receptor has received significant attention as a target for development of novel symptomatic therapies for PD. There is evidence that specific A2A antagonists reverse motor deficits and may alleviate dyskinesia in pre-clinical research models of PD (Xiao et al., 2006). Some pre-clinical research model studies suggest that A2A antagonists may also be neuroprotective (Schwarzchild et al., 2003). Several clinical trials have taken place using istradefylline, an A2A antagonist.